The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1 study of the small-molecule PD-L1 inhibitor INCB099280 in select advanced solid tumors: Updated safety, efficacy, and pharmacokinetics (PK) results.
 
Hans Prenen
Honoraria - Amgen; AstraZeneca; Merck; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Biocartis; cureteq
 
Jeannie Daniel
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Victoria Ebiana
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Jason Howe
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Xiaohua Gong
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Susan Spitz
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Antoine Italiano
Honoraria - Bayer; Daiichi Sankyo; Epizyme; IPSEN; Lilly; Novartis; Roche
Consulting or Advisory Role - Bayer; Daiichi Sankyo; Epizyme; Immune Design; Lilly; Roche
Research Funding - AstraZeneca/MedImmune; Bayer; Merck Serono; Merck Serono; MSD Oncology; PharmaMar; Roche
Patents, Royalties, Other Intellectual Property - BMS